Literature DB >> 31280968

Interleukin-23 blockade: another breakthrough in the treatment of psoriasis.

Mark Lebwohl1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31280968     DOI： 10.1016/S0140-6736(19)31513-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis.

Authors:  Yuyu Zhu; Zhigui Wu; Wei Yan; Fenli Shao; Bowen Ke; Xian Jiang; Jian Gao; Wenjie Guo; Yuping Lai; Hongyue Ma; Dijun Chen; Qiang Xu; Yang Sun
Journal:  EMBO Mol Med       Date:  2021-12-22       Impact factor: 12.137

2.  Cyclic AMP Response Element Modulator-α Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis.

Authors:  Sigrun R Hofmann; Emil Carlsson; Franz Kapplusch; Ana L Carvalho; Triantafillos Liloglou; Felix Schulze; Susanne Abraham; Sarah Northey; Susanne Russ; Anna E A Surace; Nobuya Yoshida; George C Tsokos; Christian M Hedrich
Journal:  J Immunol       Date:  2021-06-16       Impact factor: 5.422

3.  Antagonistic Peptides That Specifically Bind to the First and Second Extracellular Loops of CCR5 and Anti-IL-23p19 Antibody Reduce Airway Inflammation by Suppressing the IL-23/Th17 Signaling Pathway.

Authors:  Yingli Zhang; Rongrong Liang; Aicen Xie; Wenqian Shi; Huarong Huang; Yingqiang Zhong
Journal:  Mediators Inflamm       Date:  2020-04-28       Impact factor: 4.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.